

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4638455/publications.pdf>

Version: 2024-02-01

172  
papers

4,578  
citations

94381

37  
h-index

138417

58  
g-index

175  
all docs

175  
docs citations

175  
times ranked

5850  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Potential of Shear Wave Elastography to Reduce Unnecessary Biopsies in Breast Cancer Diagnosis: An International, Diagnostic, Multicenter Trial. <i>Ultraschall in Der Medizin</i> , 2023, 44, 162-168.	0.8	11
2	A New Practical Decision Rule to Better Differentiate <scp>BI-RADS</scp> 3 or 4 Breast Masses on Breast Ultrasound. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 427-436.	0.8	11
3	Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 1076-1084.	0.7	15
4	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. <i>Annals of Surgery</i> , 2022, 275, 576-581.	2.1	38
5	A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. <i>Annals of Surgery</i> , 2022, 276, e553-e562.	2.1	95
6	ASO Visual Abstract: Retrospective Multicenter Analysis Comparing Conventional with Oncoplastic Breast-Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 1073-1075.	0.7	0
7	Retrospective, Multicenter Analysis Comparing Conventional with Oncoplastic Breast Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 1061-1070.	0.7	19
8	ASO Visual Abstract: Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment to Reliably Exclude Residual Cancer in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 1085-1086.	0.7	0
9	The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics – An international, multicentre trial. <i>European Journal of Cancer</i> , 2022, 161, 1-9.	1.3	21
10	Breast and axillary surgery after neoadjuvant systemic treatment – A review of clinical routine recommendations and the latest clinical research. <i>Breast</i> , 2022, 62, S7-S11.	0.9	5
11	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	1.7	12
12	Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. <i>Journal of Clinical Oncology</i> , 2022, 40, 1903-1915.	0.8	31
13	Abstract PD7-02: Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery. <i>Cancer Research</i> , 2022, 82, PD7-02-PD7-02.	0.4	0
14	Abstract PD11-05: Intelligent shear-wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPIRED 002): An international, multicenter analysis. <i>Cancer Research</i> , 2022, 82, PD11-05-PD11-05.	0.4	0
15	The importance of multi-modal imaging and clinical information for humans and AI-based algorithms to classify breast masses (INSPIRED 003): an international, multicenter analysis. <i>European Radiology</i> , 2022, 32, 4101-4115.	2.3	8
16	Abstract P2-12-08: Impact of summation dose intensity product on pathologic response in patients receiving neoadjuvant chemotherapy for early breast cancer. <i>Cancer Research</i> , 2022, 82, P2-12-08-P2-12-08.	0.4	0
17	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	0.9	22
18	Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 589-598.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patientsâ€™™ and Physiciansâ€™™ Assessment from the Randomized IMRT-MC2 Trial. <i>Cancers</i> , 2022, 14, 3010.	1.7	1
20	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. <i>European Journal of Cancer</i> , 2021, 143, 134-146.	1.3	44
21	Evaluation of the FUSION-X-US-II prototype to combine automated breast ultrasound and tomosynthesis. <i>European Radiology</i> , 2021, 31, 3712-3720.	2.3	8
22	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	5.1	49
23	Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients. <i>European Journal of Radiology</i> , 2021, 135, 109468.	1.2	23
24	De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment. <i>Lancet Oncology</i> , The, 2021, 22, 435-436.	5.1	13
25	uPAâ€™PAIâ€™â€™ heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. <i>EMBO Molecular Medicine</i> , 2021, 13, e13110.	3.3	5
26	First proof-of-concept evaluation of the FUSION-X-US-II prototype for the performance of automated breast ultrasound in healthy volunteers. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 559-566.	0.8	0
27	Response Prediction to Neoadjuvant Systemic Treatment in Breast Cancerâ€™”Yet Another Algorithm?. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 654-655.	1.0	4
28	Contrast of Digital and Health Literacy Between IT and Health Care Specialists Highlights the Importance of Multidisciplinary Teams for Digital Healthâ€™”A Pilot Study. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 734-745.	1.0	15
29	Long-Term Patient Satisfaction and Quality of Life After Breast-Conserving Therapy: A Prospective Study Using the BREAST-Q. <i>Annals of Surgical Oncology</i> , 2021, 28, 8742-8751.	0.7	12
30	Do hospital type or caseload make a difference in chemotherapy treatment patterns for early breast cancer? Results from 104 German institutions, 2008â€™”2017. <i>Breast</i> , 2021, 58, 63-71.	0.9	2
31	ASO Visual Abstract: Long-Term Patient Satisfaction and Quality of Life after Breast-Conserving Therapyâ€™”A Prospective Study Using the BREAST-Q. <i>Annals of Surgical Oncology</i> , 2021, 28, 583-583.	0.7	0
32	Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 165-176.	0.3	7
33	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 214-227.	0.8	51
34	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , 2021, 11, e045239.	0.8	1
35	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , 2021, 11, e045239.	0.8	12
36	Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 425-433.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. <i>Annals of Oncology</i> , 2020, 31, 61-71.	0.6	119
38	Patients should be the tipping point of individualizing breast cancer surgery: Commentary on "Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges". <i>Annals of Oncology</i> , 2020, 31, 1264.	0.6	5
39	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology</i> , The, 2020, 21, e375-e385.	5.1	34
40	Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 848-859.	1.5	7
41	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. <i>Radiation Oncology</i> , 2020, 15, 235.	1.2	13
42	International development and implementation of a core measurement set for research and audit studies in implant-based breast reconstruction: a study protocol. <i>BMJ Open</i> , 2020, 10, e035505.	0.8	9
43	Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States. <i>Cancers</i> , 2020, 12, 2419.	1.7	9
44	Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6407.	1.8	18
45	Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 627-636.	1.1	3
46	Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?. <i>Cancers</i> , 2020, 12, 3645.	1.7	1
47	Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?. <i>European Journal of Radiology</i> , 2020, 128, 109025.	1.2	14
48	Time trends of neoadjuvant chemotherapy for early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 3049-3058.	2.3	26
49	Fatigue following radiotherapy of low-risk early breast cancer—a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). <i>Radiation Oncology</i> , 2020, 15, 134.	1.2	5
50	Surgeon's preference of subcutaneous tissue resection: most important factor for short-term complications in subcutaneous implant placement after mastectomy—results of a cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1037-1045.	0.8	1
51	De-escalation towards omission is the tipping point of individualizing breast cancer surgery. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1543-1545.	0.5	10
52	Measurement and Optimizing Cosmetic Outcomes for Breast Excisions/Factors Influencing Aesthetic Outcomes of Breast Conservation Surgery. , 2020, , 93-106.		1
53	Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 683-693.	0.4	20
54	Artificial intelligence to accurately identify breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: An international multicenter analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 565-565.	0.8	3

#	ARTICLE	IF	CITATIONS
55	IgG4-related sclerosing mastitis in a 49-year-old patient with multiple, tumor-like nodules” Diagnostic accuracy of core needle biopsy. <i>Breast Journal</i> , 2019, 25, 1251-1253.	0.4	9
56	Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 457-467.	1.1	7
57	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019, 26, 3892-3901.	0.7	29
58	Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 437-446.	1.1	5
59	ASO Author Reflections: The BREAST-Q BCT Module and Its Use in Clinical Practice. <i>Annals of Surgical Oncology</i> , 2019, 26, 788-789.	0.7	1
60	Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype. <i>Annals of Surgical Oncology</i> , 2019, 26, 4381-4389.	0.7	18
61	Psychometric validation of the Breast Cancer Treatment Outcome Scale (BCTOS-12): a prospective cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1679-1686.	0.8	5
62	Refining scores based on patient reported outcomes – statistical and medical perspectives. <i>BMC Medical Research Methodology</i> , 2019, 19, 167.	1.4	30
63	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 312-319.	0.4	15
64	Exam preparatory course for the 2nd part of the German medical examination in obstetrics and gynecology – a potential tool for the recruitment of new residents during the occupational decision process before the practical year?. <i>BMC Medical Education</i> , 2019, 19, 24.	1.0	5
65	Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index. <i>PLoS ONE</i> , 2019, 14, e0211337.	1.1	5
66	Oncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast surgeons. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1109-1114.	0.8	5
67	Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patients” First Clinical Results From a Single Center. <i>Frontiers in Oncology</i> , 2019, 9, 384.	1.3	9
68	Clinical Validation of the BREAST-Q Breast-Conserving Therapy Module. <i>Annals of Surgical Oncology</i> , 2019, 26, 2759-2767.	0.7	20
69	Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 2435-2443.	0.7	15
70	Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1490-1498.	0.8	16
71	Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice. <i>Breast</i> , 2019, 45, 89-96.	0.9	25
72	A plasma metabolite panel as biomarkers for early primary breast cancer detection. <i>International Journal of Cancer</i> , 2019, 144, 2833-2842.	2.3	50

#	ARTICLE	IF	CITATIONS
73	The Collagenase of the Bacterium Clostridium histolyticum in the Treatment of Irradiation-Induced Capsular Contracture. <i>Aesthetic Plastic Surgery</i> , 2019, 43, 836-844.	0.5	10
74	Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 429-438.	1.1	21
75	COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 135-143.	1.1	41
76	DEGUM Recommendations on Infection Prevention in Ultrasound and Endoscopic Ultrasound. <i>Ultraschall in Der Medizin</i> , 2018, 39, 284-303.	0.8	34
77	Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 48-53.	0.8	2
78	Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis. <i>European Radiology</i> , 2018, 28, 2499-2506.	2.3	21
79	Development and psychometric validation of a shorter version of the Breast Cancer Treatment Outcome Scale (BCTOS-12). <i>Breast</i> , 2018, 38, 58-65.	0.9	12
80	Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 268, e60-e61.	2.1	3
81	Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up – a case-control study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 443-447.	0.8	8
82	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. <i>Breast Care</i> , 2018, 13, 440-446.	0.8	3
83	Standards of hygiene for ultrasound-guided core cut biopsies of the breast. <i>Ultraschall in Der Medizin</i> , 2018, 39, 636-642.	0.8	4
84	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 523-537.	1.1	84
85	Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. <i>International Journal of Molecular Sciences</i> , 2018, 19, 900.	1.8	18
86	RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. <i>BMC Cancer</i> , 2018, 18, 851.	1.1	32
87	Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 971-978.	0.8	4
88	Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1451-1458.	0.8	9
89	Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres. <i>European Journal of Cancer</i> , 2017, 85, 15-22.	1.3	30
90	The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies. <i>Carcinogenesis</i> , 2017, 38, 312-320.	1.3	41

#	ARTICLE	IF	CITATIONS
91	Inter-rater reliability and double reading analysis of an automated three-dimensional breast ultrasound system: comparison of two independent examiners. Archives of Gynecology and Obstetrics, 2017, 296, 571-582.	0.8	9
92	Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials. Annals of Surgical Oncology, 2017, 24, 2855-2862.	0.7	57
93	Detection and Removal of Ceramic Clip Markers from Breast Tissue by Ultrasound-Guided, Vacuum-Assisted Minimally Invasive Biopsy in a Turkey Breast Model. Ultrasound in Medicine and Biology, 2017, 43, 341-345.	0.7	2
94	Is Mastectomy Oncologically Safer than Breast-Conserving Treatment in Early Breast Cancer. Breast Care, 2017, 12, 385-390.	0.8	19
95	First international consensus conference on standardization of oncoplastic breast conserving surgery. Breast Cancer Research and Treatment, 2017, 165, 139-149.	1.1	99
96	Investigation of Global Methylation in Peripheral Blood from Breast Cancer Patients. Journal of Molecular Biomarkers & Diagnosis, 2017, 01, .	0.4	0
97	COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.. Journal of Clinical Oncology, 2017, 35, 525-525.	0.8	1
98	Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial.. Journal of Clinical Oncology, 2017, 35, 555-555.	0.8	1
99	Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. Oncotarget, 2017, 8, 54537-54547.	0.8	34
100	Parity improves anti-tumor immunity in breast cancer patients. Oncotarget, 2017, 8, 104981-104991.	0.8	4
101	Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. OncoTargets and Therapy, 2016, Volume 9, 4173-4180.	1.0	7
102	DNA methylation array analysis identifies breast cancer associated <i>RPTOR</i> , <i>MGRN1</i> and <i>RAPSN</i> hypomethylation in peripheral blood DNA. Oncotarget, 2016, 7, 64191-64202.	0.8	33
103	Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer. International Journal of Cancer, 2016, 138, 2499-2509.	2.3	31
104	Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany. Breast Cancer Research and Treatment, 2016, 156, 289-299.	1.1	23
105	Plasma S100P level as a novel prognostic marker of metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 157, 329-338.	1.1	18
106	Do Contralateral Prophylactic Mastectomies Help Patients?. Journal of Clinical Oncology, 2016, 34, 4191-4191.	0.8	1
107	LECANDUS study (LEsion CANDidate Detection in UltraSound Data): evaluation of image analysis algorithms for breast lesion detection in volume ultrasound data. Archives of Gynecology and Obstetrics, 2016, 294, 423-428.	0.8	5
108	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer, 2016, 16, 734.	1.1	126

#	ARTICLE	IF	CITATIONS
109	Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 491-499.	1.1	54
110	Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?. <i>European Journal of Cancer</i> , 2016, 69, 142-150.	1.3	59
111	Reply to Comment on "Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques". <i>British Journal of Cancer</i> , 2016, 114, e4-e4.	2.9	0
112	Exam preparation course in obstetrics and gynecology for the German Medical State Examination: proof of concept and implications for the recruitment of future residents. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1235-1241.	0.8	4
113	Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1011-1018.	0.8	10
114	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	0.8	35
115	Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 145-152.	0.8	3
116	Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1744-1751.	0.7	33
117	Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 757-766.	0.7	15
118	Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers. <i>Acta Oncologica</i> , 2016, 55, 712-719.	0.8	20
119	Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1831-1837.	0.7	25
120	Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. <i>Oncolimmunology</i> , 2016, 5, e1057387.	2.1	38
121	Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 123-129.	0.8	5
122	Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?. <i>Annals of Surgical Oncology</i> , 2016, 23, 789-795.	0.7	84
123	Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1054-1054.	0.8	0
124	Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1118-1127.	0.7	77
125	Evaluation of an automated breast 3D-ultrasound system by comparing it with hand-held ultrasound (HHUS) and mammography. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 889-895.	0.8	41
126	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. <i>BMC Cancer</i> , 2015, 15, 403.	1.1	70

#	ARTICLE	IF	CITATIONS
127	Predictors of Residual Tumor in Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 451-458.	0.7	12
128	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. <i>British Journal of Cancer</i> , 2015, 113, 1565-1570.	2.9	83
129	Long-term objective esthetic outcome after breast-conserving therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 345-351.	1.1	46
130	Different Procedures Should Be on Offer. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2015, 112, 175.	0.6	0
131	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	1.1	45
132	Evaluation of Virtual Touch Tissue Imaging Quantification, a New Shear Wave Velocity Imaging Method, for Breast Lesion Assessment by Ultrasound. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	77
133	Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 219-224.	0.7	27
134	Quality of life and anxiety of patients affected by the PIP/Rofil Medical breast implant recall: results from a prospective monocentre cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 957-962.	0.8	0
135	Recall management of patients with Rofil Medical breast implants. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 939-945.	0.5	3
136	Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 1079-1085.	0.8	2
137	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. <i>BMC Cancer</i> , 2014, 14, 512.	1.1	65
138	Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 451-460.	1.1	8
139	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	2.2	14
140	Predictors of early poor aesthetic outcome after breast-conserving surgery in patients with breast cancer: Initial results of a prospective cohort study at a single institution. <i>Journal of Surgical Oncology</i> , 2014, 110, 801-806.	0.8	34
141	Breast Cancer Mastectomy Trends Between 2006 and 2010: Association with Magnetic Resonance Imaging, Immediate Breast Reconstruction, and Hospital Volume. <i>Annals of Surgical Oncology</i> , 2013, 20, 3839-3846.	0.7	19
142	Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1053-1060.	2.0	42
143	Interobserver reliability of automated breast volume scanner (ABVS) interpretation and agreement of ABVS findings with hand held breast ultrasound (HHUS), mammography and pathology results. <i>European Journal of Radiology</i> , 2013, 82, e332-e336.	1.2	66
144	Normal breast tissue stiffness measured by a new ultrasound technique: Virtual touch tissue imaging quantification (VTIQ). <i>European Journal of Radiology</i> , 2013, 82, e676-e679.	1.2	61

#	ARTICLE	IF	CITATIONS
145	Fluctuating Mastectomy Rates Across Time and Geography. <i>Annals of Surgical Oncology</i> , 2013, 20, 2114-2116.	0.7	19
146	Prognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up Study. <i>Annals of Surgical Oncology</i> , 2013, 20, 1865-1871.	0.7	24
147	Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. <i>Breast</i> , 2013, 22, 537-542.	0.9	48
148	Circulating microRNAs in plasma as early detection markers for breast cancer. <i>International Journal of Cancer</i> , 2013, 132, 1602-1612.	2.3	227
149	Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e76729.	1.1	112
150	Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11012-11012.	0.8	0
151	Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI?. <i>Annals of Oncology</i> , 2012, 23, 98-104.	0.6	31
152	Detected, yet not Diagnosed – Breast Cancer Screening with MRI Mammography in High-Risk Women. <i>Breast Care</i> , 2012, 7, 236-239.	0.8	3
153	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. <i>Breast Care</i> , 2012, 7, 364-369.	0.8	11
154	Recommendations for the aesthetic evaluation of breast cancer conservative treatment. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 629-637.	1.1	76
155	Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5972-5982.	3.2	231
156	Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database. <i>European Journal of Cancer</i> , 2012, 48, 1947-1956.	1.3	84
157	Predictors of resectability in breast-conserving therapy. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1023-1031.	0.8	7
158	Do Reexcisions Impair Aesthetic Outcome in Breast Conservation Surgery? Exploratory Analysis of a Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 541-547.	0.7	51
159	Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 725-734.	1.1	1
160	Objective assessment of aesthetic outcome after breast conserving therapy: Subjective third party panel rating and objective BCCT.core software evaluation. <i>Breast</i> , 2012, 21, 61-65.	0.9	36
161	Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. <i>Breast</i> , 2012, 21, 303-308.	0.9	42
162	Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 353-362.	2.0	196

#	ARTICLE	IF	CITATIONS
163	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2222-2231.	1.1	27
164	Simultaneous integrated boost for adjuvant treatment of breast cancer- intensity modulated vs. conventional radiotherapy: The IMRT-MC2 trial. <i>BMC Cancer</i> , 2011, 11, 249.	1.1	29
165	Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy. <i>European Journal of Surgical Oncology</i> , 2011, 37, 116-121.	0.5	45
166	Re: Measuring Surgery-Specific Aspects of Quality of Life in Oncologic Breast Surgery-Measuring Aesthetic and Functional Outcome Using the BCTOS (Breast Cancer Treatment Outcome Scale). <i>Breast Journal</i> , 2011, 17, 441-442.	0.4	3
167	Aesthetics in Breast Conserving Therapy: Do Objectively Measured Results Match Patients' Evaluations?. <i>Annals of Surgical Oncology</i> , 2011, 18, 134-138.	0.7	45
168	Does a Supplementary Preoperative Breast MRI in Patients with Invasive Lobular Breast Cancer Change Primary and Secondary Surgical Interventions?. <i>Annals of Surgical Oncology</i> , 2011, 18, 2143-2149.	0.7	24
169	Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 401-411.	2.0	4
170	Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature. <i>Breast Care</i> , 2011, 6, 395-398.	0.8	1
171	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. <i>Journal of Medical Genetics</i> , 2011, 48, 698-702.	1.5	5
172	Aesthetic and functional results after breast conserving surgery as correlates of quality of life measured by a German version of the Breast Cancer Treatment Outcome Scale (BCTOS). <i>Breast</i> , 2010, 19, 470-474.	0.9	52